CRNX Stock Overview A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Crinetics Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Crinetics Pharmaceuticals Historical stock prices Current Share Price US$53.94 52 Week High US$62.53 52 Week Low US$33.67 Beta 0.57 1 Month Change -4.98% 3 Month Change 6.29% 1 Year Change 50.88% 3 Year Change 92.44% 5 Year Change 112.36% Change since IPO 120.07%
Recent News & Updates
Crinetics Pharmaceuticals, Inc. Appoints Isabel Kalofonos as Chief Commercial Officer Dec 16
Crinetics Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly Dec 10
Founder notifies of intention to sell stock Dec 03
Consensus revenue estimates fall by 20% Nov 19
Third quarter 2024 earnings released: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) Nov 13
Crinetics Pharmaceuticals, Inc. to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at the North American Neuroendocrine Tumor Society Annual Meeting Nov 13 See more updates
Crinetics Pharmaceuticals, Inc. Appoints Isabel Kalofonos as Chief Commercial Officer Dec 16
Crinetics Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly Dec 10
Founder notifies of intention to sell stock Dec 03
Consensus revenue estimates fall by 20% Nov 19
Third quarter 2024 earnings released: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) Nov 13
Crinetics Pharmaceuticals, Inc. to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at the North American Neuroendocrine Tumor Society Annual Meeting Nov 13
Crinetics Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 16 Crinetics Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $400 million. Oct 09
We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely Oct 02
Chief Financial Officer notifies of intention to sell stock Sep 29
Crinetics Pharmaceuticals, Inc. Submits New Drug Application for Paltusotine for the Treatment of Acromegaly Sep 27
Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech Aug 12 Crinetics Pharmaceuticals, Inc. Announces Marc Wilson Will Be Transitioning from His Role as Chief Financial Officer Aug 09
Chief Financial Officer notifies of intention to sell stock Jul 28
Crinetics Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 19
Chief Operating Officer notifies of intention to sell stock Jul 17 Crinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from Russell 2500 Value Index
Chief Commercial Officer notifies of intention to sell stock Jun 23 Crinetics Pharmaceuticals, Inc. Presents New Data At ENDO 2024 That Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
Price target increased by 7.8% to US$66.43 Jun 04
Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation Jun 01
Crinetics Pharmaceuticals, Inc. Appoints Robert M. Cuddihy as Senior Vice President of Medical Affairs May 31
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts May 25
Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data May 23
Price target increased by 8.2% to US$61.50 May 12
Full year 2023 earnings released: US$3.69 loss per share (vs US$3.15 loss in FY 2022) May 10
Founder notifies of intention to sell stock May 10
Price target increased by 10% to US$59.79 May 07
Crinetics Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Crinetics Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024 Apr 28
Chief Development Officer notifies of intention to sell stock Apr 17
Chief Financial Officer notifies of intention to sell stock Mar 21
Price target increased by 7.8% to US$57.23 Mar 20
Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly Mar 19
Price target increased by 9.1% to US$54.46 Mar 13
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome Mar 13
Consensus revenue estimates decrease by 88%, EPS upgraded Mar 10
Consensus revenue estimates decrease by 89%, EPS upgraded Mar 06
Chief Medical Officer notifies of intention to sell stock Mar 01
Full year 2023 earnings: EPS and revenues miss analyst expectations Feb 29
Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade) Feb 29 Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors Feb 29
Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors Feb 28
Crinetics Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 15
Chief Medical Officer notifies of intention to sell stock Feb 14
Chief Financial Officer notifies of intention to sell stock Jan 04
Crinetics Pharmaceuticals, Inc. Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome Dec 19
Chief Medical Officer notifies of intention to sell stock Dec 17
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 09
Chief Financial Officer notifies of intention to sell stock Nov 03
Chief Medical Officer notifies of intention to sell stock Oct 24
Chief Medical Officer notifies of intention to sell stock Oct 20
New minor risk - Shareholder dilution Sep 13
Crinetics' Once-Daily Oral Paltusotine Achieves the Primary and All Secondary Endpoints in the Phase 3 Pathfr-1 Study Evaluating Treatment of Patients with Acromegaly Sep 12
Price target increased by 8.2% to US$46.78 Sep 12
Consensus revenue estimates fall by 18% Aug 15
Price target decreased by 7.4% to US$43.63 Aug 13
New minor risk - Shareholder dilution Aug 09
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 08
Founder recently sold US$1.0m worth of stock Jul 16
Founder notifies of intention to sell stock Jul 14
Founder recently sold US$1.0m worth of stock Jun 25
Crinetics Pharmaceuticals, Inc. Presents Efficacy, Safety and Patient-Reported Outcome Data At ENDO 2023 Jun 22
Founder notifies of intention to sell stock Jun 19
Consensus revenue estimates increase by 154% May 12
Chief Development Officer notifies of intention to sell stock Apr 10
Chief Development Officer recently sold US$133k worth of stock Apr 06
Consensus EPS estimates fall by 13% Mar 09
Consensus EPS estimates fall by 12% Mar 07
Founder & Chief Scientific Officer notifies of intention to sell stock Dec 10
Crinetics Pharmaceuticals, Inc. Provides Update on Crn04777 Program Nov 29
Consensus revenue estimates fall by 37% Nov 21
High number of new directors Nov 16
Founder & Chief Scientific Officer notifies of intention to sell stock Oct 22
Crinetics Pharmaceuticals, Inc. Completes Enrollment in Phase 3 PATHFNDR-1 Study Oct 14
Founder & Chief Scientific Officer notifies of intention to sell stock Oct 08
Crinetics Pharmaceuticals, Inc Announces that Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism Oct 07
Crinetics Pharmaceuticals Appoints Dana Pizzuti as Chief Development Officer Oct 04
Founder & Chief Scientific Officer notifies of intention to sell stock Sep 24
Founder & Chief Scientific Officer notifies of intention to sell stock Sep 10
Consensus forecasts updated Sep 07
Crinetics Pharmaceuticals Announces New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly Sep 07
Consensus revenue estimates fall by 28% Aug 19
Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M Aug 12
Independent Director exercised options and sold US$111k worth of stock Jul 16 Shareholder Returns CRNX US Biotechs US Market 7D 2.3% -3.3% -0.4% 1Y 50.9% -2.7% 24.8%
See full shareholder returns
Return vs Market: CRNX exceeded the US Market which returned 24.8% over the past year.
Price Volatility Is CRNX's price volatile compared to industry and market? CRNX volatility CRNX Average Weekly Movement 5.8% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: CRNX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CRNX's weekly volatility (6%) has been stable over the past year.
About the Company Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing’s disease.
Show more Crinetics Pharmaceuticals, Inc. Fundamentals Summary How do Crinetics Pharmaceuticals's earnings and revenue compare to its market cap? CRNX fundamental statistics Market cap US$5.00b Earnings (TTM ) -US$277.91m Revenue (TTM ) US$1.04m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CRNX income statement (TTM ) Revenue US$1.04m Cost of Revenue US$50.64m Gross Profit -US$49.60m Other Expenses US$228.31m Earnings -US$277.91m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.00 Gross Margin -4,774.21% Net Profit Margin -26,747.83% Debt/Equity Ratio 0%
How did CRNX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 00:52 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Crinetics Pharmaceuticals, Inc. is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird Joshua Schimmer Cantor Fitzgerald & Co. Charles Duncan Cantor Fitzgerald & Co.
Show 14 more analysts 
